Stock Events

Minerva Neurosciences 

$2.58
57
-$0.09-3.37% Thursday 20:00

Statistics

Day High
2.68
Day Low
2.58
52W High
13.49
52W Low
2.26
Volume
5,805
Avg. Volume
15,684
Mkt Cap
19.16M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

4
NOV
Earnings
 

Earnings

4NovExpected
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Next
-1.63
-1.23
-0.84
-0.44
Expected EPS
-1.01
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NERV. It's not an investment recommendation.
Alphabet
78096
GOOGL
Apple
67979
AAPL
Microsoft
63406
MSFT
Amazon
59137
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sage Therapeutics
SAGE
Mkt Cap514.65M
Sage Therapeutics focuses on central nervous system disorders, directly competing in the same therapeutic area as Minerva Neurosciences.
Acadia Pharmaceuticals
ACAD
Mkt Cap2.75B
Acadia Pharmaceuticals specializes in neurology, competing with Minerva in developing treatments for central nervous system disorders.
Alkermes
ALKS
Mkt Cap4.68B
Alkermes works on central nervous system (CNS) diseases, including schizophrenia and depression, areas Minerva is also targeting.
BridgeBio Pharma
BBIO
Mkt Cap5.24B
BridgeBio Pharma targets genetic diseases and precisely engineered drugs that could overlap with Minerva's focus on neurological conditions.
Biogen
BIIB
Mkt Cap29.83B
Biogen is a major player in neurology, directly competing with Minerva in the broader market for neurological disease treatments.
AMGEN
AMGN
Mkt Cap179.38B
Amgen, with its broad focus on biopharmaceuticals, has ventures into neuroscience, making it a competitor in the neurology space.
Leap Therapeutics
LPTX
Mkt Cap110.97M
Leap Therapeutics, while primarily focused on cancer, is expanding into other areas, including potential treatments for neurological disorders.
Insmed
INSM
Mkt Cap13.14B
Insmed incorporates a wide range of therapeutic areas, including neurological diseases, indirectly competing with Minerva.
Ionis Pharmaceuticals
IONS
Mkt Cap6.97B
Ionis Pharmaceuticals specializes in RNA-targeted drug discovery, which includes treatments for neurological disorders, competing with Minerva's focus.
Palatin Technologies
PTN
Mkt Cap31.57M
Palatin Technologies, though focused on different areas, has shown interest in expanding into central nervous system disorders, potentially competing with Minerva.

Analyst Ratings

5$Average Price Target
The highest estimate is $5.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

About

Health Technology
Biotechnology
Manufacturing
Pharmaceutical Preparation Manufacturing
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Show more...
CEO
Remy Luthringer
Employees
9
Country
US
ISIN
US6033801068

Listings

XNAS
US
NERV
F
DE
4MNA.F